Recent news and posts
Med Tech-related technology assessments from NICE in the first half of July 2017
The following technology assessments were released by the National Institute for Health and Care Excellence (NICE) in first two weeks of July 2017:
Medtech Innovation Briefings for Nasal Alar SpO2 sensor (device for monitoring a person's peripheral oxygen saturation (SpO2) with a pulse oximeter), Arctic Sun 5000 (device used for therapeutic hypothermia after cardiac arrest), L-Dex U400 (bioimpedance spectroscopy for early detection of unilateral lymphoedema in the limbs after treatment for breast cancer) and FreeStyle Libre (flash glucose monitoring system for measuring interstitial fluid glucose levels in diabetes).
MedTech Innovation Briefing is the NICE's advice program for innovative technologies. It provides an overview of clinical effectiveness, safety and cost. It does not offer a formal guidance and it therefore does not provide any recommendations.
Clinical guideline for Parkinson’s disease in adults covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.
Diagnostic Guidance for new generation cardiac CT scanners has been updated. NICE recommended Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash as an option for first-line imaging of the coronary arteries in people with suspected stable coronary artery disease (with an estimated likelihood of coronary artery disease of 10–29%) in whom imaging with earlier generation CT scanners is difficult. Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash are recommended as an option for first-line evaluation of disease progression, to establish the need for revascularisation, in people with known coronary artery disease in whom imaging with earlier generation CT scanners is difficult.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.